Cancer Vaccines with Potential

Premium

When Dendreon came out with its prostate cancer vaccine Provenge, researchers jumped on the vaccine bandwagon and Wall Street salivated at the thought of the billions of dollars it was going to make, says Robert Langreth at the Forbes Treatments blog. But the complicated preparation for the treatment and the $93,000 price tag — not to mention confusion over how it works since it extends life without slowing tumor growth — have caused big pharmaceutical companies to shy away from trying to develop a vaccine of their own, Langreth adds.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting intepretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.